Status:
COMPLETED
PharmacoMRI of Parkinson Disease
Lead Sponsor:
Northwestern University
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
NA
Brief Summary
Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that compariso...
Detailed Description
Subject participation includes two 25-30 minute MRI scans. The subject will arrive in the "off" state (PD medications withheld for approximately 12 hours prior to the scan). Following the initial scan...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's Disease (PD)
- Older than 30 years of age at the time of diagnosis
- Hoehn and Yahr stage greater than or equal to 2.5
- PD duration greater than 3 years
- Stable regimen of PD medications for at least 2 weeks prior to imaging
- PD medications include carbidopa-levodopa
Exclusion
- Patients with a diagnosis of other neurodegenerative conditions
- Patients unwilling or unable to give informed consent
- Contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo MRI scan
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01528592
Start Date
June 1 2011
End Date
July 1 2012
Last Update
May 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611